Davenport & Co’s Enzo Biochem, Inc. ENZ Stock Holding History

Davenport & Co’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-158,325	Closed	-$652K	–	690
2018 Q3	$652K	Buy	158,325 +25,325	+19%	+$115K	0.01%	391
2018 Q2	$690K	Buy	133,000 +25,575	+24%	+$156K	0.01%	374
2018 Q1	$589K	Buy	+107,425	New	+$757K	0.01%	407

Other funds holding ENZ

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Davenport & Co's ENZ Position: Q4 2018 in Review

Davenport & Co sold out of Enzo Biochem, Inc. (ENZ) in Q4 2018, closing a stake of 158,325 shares — an estimated $652K sold.

Davenport & Co first reported a position in ENZ in Q1 2018 and held it in 3 quarters. The position peaked at $690K in Q2 2018. 91 funds tracked by Wall St. Rank hold ENZ as of Q4 2018.

Davenport & Co reported no remaining Enzo Biochem, Inc. position as of Q4 2018 after selling out during the quarter.
Davenport & Co sold 158,325 Enzo Biochem, Inc. shares in Q4 2018, an estimated $652K.
Davenport & Co first reported a position in Enzo Biochem, Inc. in Q1 2018 and held it in 3 quarters.
Davenport & Co's Enzo Biochem, Inc. position peaked at $690K in Q2 2018.
91 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2018.

Based on Davenport & Co's 13F filing for Q4 2018, filed 28 Jan 2019.